<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905916</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-JYL-05-07</org_study_id>
    <nct_id>NCT02905916</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary
      prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia (FN)</measure>
    <time_frame>30days after PEG-rhG-CSF administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">217</enrollment>
  <condition>Mammary Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Bone Tumour</condition>
  <condition>Gynecological Tumors</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with age between 18 and 70 years.

          2. Breast cancer, lymphoma, bone tumor or Gynecologic tumor patients.

          3. With multi-cycle chemotherapy.

          4. With III/IV degree neutropenia after the last cycle of chemotherapy and plans to use
             the same regimen in the subsequent cycles.FN risk of the chemotherapy regimens is
             ≥20%，or 10%≤FN risk＜20% and has high risk factors associated with FN.

          5. KPS score≥ 70.

          6. Expected to survive more than 3 months.

          7. No hematologic system disease and ANC≥1.5×10E9/L, PKT≥80×10E9/L, Hb≥ 75g/L,
             WBC≥3×10E9/L, and no bleeding tendency.

          8. Written informed consent are acquired. -

        Exclusion Criteria:

          1. With infection or systemic antibiotic therapy 72h before chemotherapy.

          2. With any abnormal hematopoietic function.

          3. Received transplantation within 3 months.

          4. Suffered from other malignant tumor or brain metastases.

          5. TBIL, ALT,AST &gt; 2.5×ULN; if it were caused by liver metastases, TBIL, ALT,AST &gt;5×ULN.

          6. Cr &gt;1.5 ×ULN.

          7. Sensitive to the product or other genetically engineered biological products from
             Escherichia coli strains.

          8. Mental or nervous system disorders.

          9. Refused to accept contraceptive measures.

         10. Other situations that investigators consider as contra-indication for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Zhu, MD</last_name>
    <phone>+86-10-88196596</phone>
    <email>zj@bjcancer.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu, MD</last_name>
      <phone>+86-10-88196596</phone>
      <email>zj@bjcancer.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

